Contera Pharma, a subsidiary of Bukwang Pharmaceutical, attracts investment from Medici Investment

  • Wednesday, July 10, 2019

  • 3 million dollars invested by Medici Investment

    European Clinical phase 2 study of JM-010 to treat dyskinesia in Parkinson’s disease has been started


  • Contera Pharma ApS (“Contera”), a subsidiary of Bukwang Pharmaceutical, has booked 3 billion KRW series A financing from Medici Investment. The proceeds from the financing will go to speed up the European JM-010 phase 2 clinical study.


  • Medici Investment Co., Ltd. is a combined private equity and venture capital company. The firm has been growing up fast and is well known for its performance in identifying excellent investment opportunities.

  • Contera, a Danish company focusing on developing treatment for CNS (Central Nervous System) disorders, was acquired by Bukwang Pharmaceutical in 2014. Contera is currently developing JM-010 as a treatment for dyskinesia in Parkinson’s disease, which is a common side effect found in patients with Parkinson’s disease who have been constantly treated with L-DOPA.

  • Market for dyskinesia in Parkinson’s disease is estimated around 2 billion dollars USD with Gocovri® (generic name: Amantadine) is the only product approved by the USFDA to date.

  • Through phase 1 PK study in Germany and clinical proof of concept (PoC) study in South Africa, JM-010 has demonstrated excellent antidyskinetic effect without notable safety concern so far. Recently, an investigators’ meeting for the initiation of European phase 2 clinical study has been held in Germany. The study will enroll patients in Germany, France and Spain and is expected to be completed within 2 years. Additionally, a US phase 2 clinical study has also been planned. The pre-IND meeting has been conducted with the USFDA and Bukwang aims to submit the IND in second half of 2019.

  • An official of Bukwang says “Through this initial financing, we expect Contera Pharma to continue its growth as a specialist in CNS drug development. In addition, Bukwang will also implement its global open innovation strategy more actively and strengthen its European networks”

    Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries

  • Wednesday, June 26, 2019

  • to be completed within 2 years

  • Bukwang Pharmaceutical (“Bukwang”) announced today that the phase 2 clinical study of JM-010, a new potential treatment for dyskinesia in Parkinson’s disease, has recently been initiated. JM-010 is currently developed by Copenhagen-based Contera Pharma, a subsidiary of Bukwang.

  • About 90% of patients who have been taking L-dopa for 10 years or longer develop dyskinesia, a difficult to treat condition and thus an unmet medical need. JM-010, which is expected to treat this condition, has been tested in phase 1 PK study and phase 2a study successfully in Germany and South Africa, respectively, and has been approved in the fourth quarter last year by relevant competent authorities to initiate phase 2 clinical study in Germany, France, and Spain.

  • Bukwang has also held investigators’ meeting in Germany in late April 2019 and the first Site Initiation Visit has been successfully conducted at Klinikum Hanau Hospital in Germany on June 12th. By speeding up the patient registration, Bukwang expects the phase 2 clinical study will be completed within 2 years.

  • During the investigator meeting, Bukwang observed there was high expectation from participating investigators because there is no drug approved to treat dyskinesia in Europe so far. Bukwang aims to deliver JM-010 as a ‘best-in-class’ treatment choice that offer complete solution to treat dyskinesia in Parkinson’s disease.

    Bukwang Announces approval of Clinical Trial Application by European authority to initiate Phase 2 study of JM-010

  • Monday, October 22, 2018

  • Bukwang Pharmaceutical announces that the company’s application to conduct phase 2 clinical study for new CNS drug candidate 'JM-010' has recently been approved by French authority. The study is planned to include major European countries, including Germany, France, and Spain, with approvals from other countries are also expected to be completed within this month with first patient is expected to be enrolled early next year.

  • JM-010 is a new drug candidate developed by Contera Pharma, a subsidiary of Bukwang Pharmaceuticals based in Copenhagen, to treat dyskinesia in Parkinson’s disease. As a number of Parkinson’s disease patients continues to grow, US market size of dyskinesia, citing Adamas Pharmaceutical whose dyskinesia product ‘Gocovri’ (amantadine SR capsule) is currently marketed in the US, is expected to be approximately 2 trillion won.

  • JM-010 has been tested in phase 1 PK study and clinical proof of concept study demonstrating excellent efficacy without safety concern observed so far. Bukwang Pharmaceutical has been accelerating the development of JM-010 and is aiming to deliver JM-010 as a ‘best-in-class’ treatment choice that offer complete solution to treat dyskinesia in Parkinson’s disease patients.

    Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered patents on a therapeutic candidate for Levodopa-induced dyskinesia in Parkinson’s disease. - International application and registration of patents on therapeutic use and composition, formulations and metabolites for Levodopa-induced dyskinesia in Parkinson’s disease.

  • Wednesday, January 31, 2018

  • Bukwang said it registered patents on the use and composition of ‘JM-010’ with Korean Intellectual Property Office (Title : Combinations of serotonin receptor agonists for treatment of movement disorders). ‘JM-010’ is a treatment for ‘Levodopa-induced dyskinesia in Parkinson’s disease’ developed by Bukwang’s subsidiary named Contera Pharma ApS, which is a Danish bio venture specialized in CNS(Central Nervous System).

  • Bukwang filed three international patents regarding ‘JM-010’: Use and composition, formulations and metabolite patents. The patent for use and composition, which has been only recently registered in Korea, has been already registered in the US, Europe(32 countries), Australia, China and Japan. Furthermore, it is under review and awaiting registration approval in other countries. Also, the patent for formulations has been registered in Europe (21 countries), Australia, and China and Japan, and is under review for registration in other countries.

  • LID refers to Levodopa-induced dyskinesia, a common side effect found in Parkinson’s disease patients who have been constantly treated with L-DOPA. ‘JM-010’, a treatment for LID, has successfully completed phase 2a study and is preparing for the global phase 2b study mainly in US and Europe.

  • A representative from Bukwang said, “The registration of ‘JM-010’ patents in major countries including the US and Europe would provide Bukwang with an opportunity to further expand its business internationally and become acknowledged for its technological originality and novelty.”